BioEclosion aims at enhancing quantitative diagnostics based on user-friendly devices towards novel molecular biomarkers for the rapid detection of emerging disease affecting global health. The company started its activity with several patents, the most important being Celifast: a non-invasive approach for the detection of celiac disease. Addressing point of care attention of patients, the core technology has been successfully validated and the team is currently working on further development for commercialization.